No Data
No Data
The gross margin of injection products in the solution category has declined, and the imeik technology development's Q2 performance growth rate has dropped to single digits| Speed reading announcement.
①Imeik Technology Development's H1 revenue and net income growth rate slowed down. ②The gross margin of solution injection products has declined, and its proportion in total revenue has further decreased. ③In addition to laying out research and development pipelines for botulinum toxin, GLP-1 drugs, the company is also further expanding in the medical beauty equipment field.
Annual Financial Report
FINANCIAL STATEMENTS
How long can the American customer love myth of high growth last? | Insight Research
Despite 3 consecutive years of high performance growth, market concerns about Aimeike's future growth momentum have not been resolved.
Is the healthcare market recovering? Mindray Healthcare acquires control of Whitney Healthcare at 25% premium | Insight Research
In the new year, A was born, and the leading device company Mindray entered the cardiovascular field at a premium.
Behind the slowdown in Aimeike's growth rate in the 3rd quarter: “Women's Maotai” can't handle the slump in consumption?
Demand weakens